Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptor beta variable 6 (TRBV6) is a germline-encoded segment of the variable region of the beta chain in the alpha-beta T-cell receptor (TCR) complex. It plays a fundamental role in adaptive immunity by participating in antigen recognition and the subsequent activation of T lymphocytes upon binding to peptide-major histocompatibility complex (pMHC) molecules. Unlike highly variable, clonally rearranged TCR regions, TRBV6 represents a conserved, non-clonal target that is consistently expressed across individuals and is highly prevalent among tumor-infiltrating lymphocytes (TILs) in various malignancies. In oncology, TRBV6 has emerged as a novel therapeutic target for precision immunotherapy. Drugs like invikafusp alfa (STAR0602), a first-in-class bispecific dual T-cell agonist, target TRBV6 to selectively activate and expand Vβ6-positive CD4+ and CD8+ T-cell populations. This selective activation, combined with co-stimulation (such as via fused IL-2), drives the expansion of clonally diverse effector memory T cells, enhancing anti-tumor immunity and promoting durable tumor clearance even in checkpoint inhibitor-resistant cancers.
Invikafusp alfa (STAR0602) is a bispecific dual T-cell agonist that selectively binds and activates Vβ6/Vβ10 T-cell receptors while delivering a co-stimulatory interleukin-2 (IL-2) signal in cis, promoting the expansion of clonally diverse effector memory T cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor beta variable 6 (TRBV6).